Clinical efficacy and safety of oxaliplatin combined with 5 -fluorouracil in the treatment of advanced esophageal cancer
10.13699/j.cnki.1001-6821.2016.06.009
- VernacularTitle:奥沙利铂联合5－氟尿嘧啶治疗中晚期食管癌的临床疗效及安全性评价
- Author:
Ming-Jin SHE
1
;
Zu-Sheng MA
;
Gui-Zhi LI
;
Wen-Bo ZHU
;
Meng-Meng CHENG
;
Gao-Ming QIN
Author Information
1. 武警安徽总队医院肿瘤科
- Keywords:
esophageal cancer;
oxaliplatin;
5-fluorouracil;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(6):508-510
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of oxaliplatin combined with 5 -fluorouracil ( 5 -FU ) in the treatment of advanced esophageal cancer.Methods Sixty -five patients with advanced esophageal cancer were randomly divided into control group (n=32) and treatment group(n=33).The patients in two groups were treated with conventional fractionated radiotherapy at 2.0 Gy, with a total dose of 56-66 Gy.Chemotherapy was delivered on the first day of radio-therapy.Control group was received 52.5 mg · m-2 · d -1 cisplatin on day 1 +500 mg · m-2 · d -1 5 -Fu on day 1 -5 through intravenous drip.Treatment group was received 85-100 mg · m-2 · d-1 oxaliplatin through intravenous infusion two hours on day 1 +500 mg · m -2 · d -1 5-FU on day 1 -5 through intravenous drip.Every 4 weeks was a cycle, all received two cycles of chemotherapy.The clinical efficacy and incidence of adverse drug reactions between two groups were compared.Results After treatment, total effective rates were 81.80% and 75.00%in treatment group and control group, disease control rates were 96.97% and 93.75% in treatment group and control group, one year survival rates were 77.30%and 68.20%in treatment group and control group, with no statistical difference between the two groups( P>0.05).After treatment, the occurrence rate of nausea and vomiting in treatment group was signifi-cantly lower than that in control group(34.60%vs 62.50%, P<0.05) .The occurrence rate of sensory neuropathy in treatment group was significantly higher than that in control group(24.00%vs 0, P<0.05).Conclusion Concurrent chemoradiation with oxaliplatin and 5-FU for the treatment of advanced esophageal cancer exhibited a definitive clini-cal efficacy with clinical manageable adverse drug reactions.
